Why Tilray Stock Skyrocketed 54% Last Week

Here’s why Tilray (TSX:TLRY) stock popped by 54% last week to become the top-performing stock on the TSX.

| More on:

What happened?

The shares of Tilray (TSX:TLRY)(NASDAQ:TLRY) staged a massive rally last week to post their biggest weekly gains since the completion of its Aphria acquisition in May 2021. TLRY stock jumped by a solid 54% in the week ended on March 25 to settle at $10.72 per share — its highest closing level in more than three months. With this, Tilray stock, which was down by 20% a couple of sessions ago, is now trading with 20.2% year-to-date gains.

So what?

While Tilray was the biggest gainer among cannabis stocks last week, the shares of its peers like Aurora Cannabis, Canopy Growth, and Cronos Group also saw strong double-digit gains. While Aurora Cannabis ended the week with 23.5% gains in the week ended on March 25, Canopy Growth and Cronos Group shares popped by about 20.7% and 15.9%, respectively.

This rally in pot stocks on the TSX started on March 24 after a Marijuana Moment report claimed that “the U.S. House of Representatives plans to vote on a bill to federally legalize marijuana for the second time in history.” According to the news report, the House vote on this critically important bill for the marijuana industry is likely to take place this week. Investors’ high hopes from the expected House vote triggered a buying spree in Tilray and other cannabis stocks last week.

Now what?

Tilray is one of the largest cannabis companies in the world by market cap. In January, Tilray revealed that it has achieved $70 million in cost synergies to date from its merger with Aphria. Its leading position in several key cannabis markets could help Tilray post strong top-line growth in the coming years.

That said, if you have been following the cannabis industry for some time, you might already be aware that even a small news or industry update usually makes pot stocks highly volatile. While the latest news about the House vote on the marijuana legalization bill is certainly a big one, its outcome is still unknown. That’s why conservative investors may want to remain cautious before making any positions in Tilray or any other pot stock in the near term, as more related updates could keep them extremely volatile.

The Motley Fool has no position in any of the stocks mentioned. Fool contributor Jitendra Parashar has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »